Ellis Pharma has successfully negotiated the exclusive supply of Foscavir® (foscarnet) with Clinigen Healthcare, for the Middle East and North African (MENA) market sector.
Foscavir® is licensed for the treatment of cytomegalovirus (CMV) retinitis in HIV patients, and acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients. Its active ingredient is the anti-viral foscarnet (sodium).
Clinigen Healthcare acquired the global licences and rights to Foscavir® from Astra Zeneca in 2010. Now, following this latest deal, Ellis Pharma has become the exclusive supplier for Foscavir® in the MENA region and will be supplying to hospitals, clinics and other medical organisations.
Gary Campbell, Business Development Director for Ellis Pharma, said: “We’re very pleased to have successfully secured this exclusive contract. We’re looking forward to a very positive future as we look to expand our operations in the Middle East to offer bespoke product and service. Becoming the exclusive supplier of Foscavir in the Middle East is an important part of achieving this.”
Ellis Pharma is a global pharmaceutical supplier. The company delivers an innovative global pharmaceutical supply chain solution to healthcare organisations worldwide, including private healthcare organisations in the MENA region. The company draws on its international network of pharmaceutical suppliers to source and deliver its clients with a range of pharmaceuticals and equipment.
Clinigen Healthcare is part of the Clinigen Group, a UK-based specialty pharmaceutical services group focused on getting medicines to patients and their physicians. Clinigen Group was formed in 2010, with the merger of Clinigen Healthcare, Clinigen Pharma and Keats Healthcare.